We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
+14.95%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$8.78B
AUM Growth
-$802M
Cap. Flow
-$1.61B
Cap. Flow %
-18.35%
Top 10 Hldgs %
33.27%
Holding
157
New
20
Increased
27
Reduced
40
Closed
17

Top Buys

Rank Stock Value
1
SHPG
Shire pic
SHPG
+$131M
2
MRK icon
Merck
MRK
+$97.5M
3
EW icon
Edwards Lifesciences
EW
+$97.4M
4
AGN.PRA
Allergan plc
AGN.PRA
+$76.2M
5
BOLD
Audentes Therapeutics, Inc
BOLD
+$72.9M

Top Sells

Rank Stock Value
1
HCA icon
HCA Healthcare
HCA
+$213M
2
BMY icon
Bristol-Myers Squibb
BMY
+$184M
3
ABBV icon
AbbVie
ABBV
+$152M
4
BSX icon
Boston Scientific
BSX
+$141M
5
AGN
Allergan plc
AGN
+$138M

Sector Composition

Rank Sector Weight
1 Healthcare 92.67%
2 Financials 0.39%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BIIB icon
1
Biogen
BIIB
$32B
$418M 4.76%
1,333,900
-166,500
-11% -$49.3M
BSX icon
2
Boston Scientific
BSX
$68.8B
$410M 4.67%
17,211,700
-5,917,500
-26% -$141M
AMGN icon
3
Amgen
AMGN
$212B
$406M 4.63%
2,436,700
-596,800
-20% -$101M
ALXN
4
DELISTED
Alexion Pharmaceuticals
ALXN
$323M 3.68%
2,638,011
-343,400
-12% -$44.2M
CELG
5
DELISTED
Celgene Corp
CELG
$308M 3.51%
2,948,577
+543,900
+23% +$58.9M
ABBV icon
6
AbbVie
ABBV
$471B
$267M 3.04%
4,229,900
-2,343,200
-36% -$152M
MRK icon
7
Merck
MRK
$324B
$219M 2.49%
3,675,126
+1,667,682
+83% +$97.5M
SHPG
8
DELISTED
Shire pic
SHPG
$206M 2.35%
1,063,351
+669,342
+170% +$131M
ICPT
9
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$184M 2.1%
1,120,000
– –
WMGI
10
DELISTED
Wright Medical Group Inc
WMGI
$180M 2.06%
7,356,233
+811,070
+12% +$18.7M
AGN
11
DELISTED
Allergan plc
AGN
$179M 2.04%
778,690
-565,925
-42% -$138M
A icon
12
Agilent Technologies
A
$39.6B
$175M 1.99%
3,714,800
+149,600
+4% +$6.98M
INCY icon
13
Incyte
INCY
$25.3B
$174M 1.99%
1,850,178
-474,500
-20% -$40M
EW icon
14
Edwards Lifesciences
EW
$49.2B
$166M 1.89%
4,119,600
+2,585,400
+169% +$97.4M
LLY icon
15
Eli Lilly
LLY
$1.09T
$164M 1.87%
2,040,500
+563,700
+38% +$45.1M
PBYI icon
16
Puma Biotechnology
PBYI
$398M
$160M 1.82%
2,383,525
-580,500
-20% -$29.4M
GILD icon
17
Gilead Sciences
GILD
$166B
$159M 1.81%
2,010,700
-1,062,200
-35% -$86.3M
IRWD icon
18
Ironwood Pharmaceuticals
IRWD
$602M
$158M 1.8%
11,879,106
– –
MOH icon
19
Molina Healthcare
MOH
$10.6B
$154M 1.75%
2,634,700
+796,700
+43% +$43.9M
WCG
20
DELISTED
Wellcare Health Plans, Inc.
WCG
$146M 1.66%
1,248,000
-670,500
-35% -$74.9M
REGN icon
21
Regeneron Pharmaceuticals
REGN
$73.1B
$143M 1.63%
355,300
-154,600
-30% -$62M
VRTX icon
22
Vertex Pharmaceuticals
VRTX
$124B
$141M 1.6%
1,612,000
-577,300
-26% -$54.6M
ISRG icon
23
Intuitive Surgical
ISRG
$128B
$136M 1.55%
1,690,200
-990,000
-37% -$75.8M
TMO icon
24
Thermo Fisher Scientific
TMO
$215B
$130M 1.48%
816,500
-560,700
-41% -$86.4M
PFE icon
25
Pfizer
PFE
$144B
$120M 1.36%
3,722,939
-749,921
-17% -$25.1M
1
2 3 4 5

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

OrbiMed's Q3 2016 Portfolio in Review

As of Q3 2016, OrbiMed held 157 positions worth $8.78B, down 8.4% from $9.58B the previous quarter. Its ten largest holdings account for 33% of the portfolio.

OrbiMed withdrew a net $1.61B in Q3 2016, closing 17 positions and reducing 40 holdings. Its most notable exit was RELYPSA INC COM, an estimated $137M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, up from 89% a quarter earlier, followed by Financials.

Against the trend, OrbiMed opened a new position in Allergan plc worth $72.5M.

  • OrbiMed's largest Q3 2016 buy was Allergan plc: 88,200 shares worth $72.5M.
  • OrbiMed added most to Shire pic in Q3 2016, an estimated $131M increase.
  • OrbiMed's biggest Q3 2016 reduction was HCA Healthcare, cutting an estimated $213M.
  • OrbiMed fully exited RELYPSA INC COM in Q3 2016, selling an estimated $137M.
  • OrbiMed's ten largest holdings make up 33% of its $8.78B portfolio in Q3 2016.
  • OrbiMed opened 20 new positions and closed 17 in Q3 2016.
  • OrbiMed's portfolio value fell 8.4% quarter-over-quarter to $8.78B.

Based on OrbiMed's 13F filing for Q3 2016, filed 14 Nov 2016.